Delivery Order SPE2DB22D1002-SPE2DB25FLFB6
- Not listed
- The Defense Logistics Agency awarded a $3,689.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Entresto 24 mg-26 mg tablets (60-count supply) on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-competitive delivery order was placed against AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled at...
- The Defense Logistics Agency awarded a $68,784.07 delivery order to AmerisourceBergen Drug Corp for the supply of Entresto 49 mg-51 mg tablets (180-count units) on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a direct fulfillment under the company's broader pharmaceutical supply arrangements. The place of performance is AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Entresto 24 mg-26 mg tablets (60-count packaging) with a ceiling value of $5,642.09. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for ultimate completion by July 29, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $25,914.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 180 tablets of Entresto 24 mg-26 mg, a cardiovascular medication used to treat heart failure. The contract was awarded on July 30, 2025, with an ultimate completion date of July 31, 2025, and was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a...
- The Defense Logistics Agency awarded a $7,996.94 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Entresto 97 mg-103 mg tablets (180-count). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 29, 2025. AmerisourceBergen will perform this work from its corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under a larger contract vehicle...
- The Defense Logistics Agency awarded a $2,342.93 delivery order to AmerisourceBergen Drug Corp for 180 tablets of Entresto 24 mg-26 mg on July 24, 2025, with completion scheduled for July 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procurement procedures. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $8,037.83 to AmerisourceBergen Drug Corp for the supply of Entresto 97 mg-103 mg tablets (180-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Entresto 24 mg-26 mg tablets (180-count units) with a ceiling value of $3,461.44. This is a firm fixed-price delivery order with an ultimate completion date of August 4, 2025, and no set-aside designation was applied. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Entresto 49 mg-51 mg tablets (180 count) under a firm fixed price contract valued at $65,700.48, with a completion date of July 24, 2025. This competitively awarded, non-set-aside delivery order represents a continuation of AmerisourceBergen's critical role as a pharmaceutical distributor supporting federal medical procurement needs. The contract is performed at the...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Entresto 24 mg-26 mg tablets (60 count) under a firm fixed-price contract valued at $16,230.90, with completion expected by July 24, 2025. This non-set-aside competitive award represents a child delivery order executed through AmerisourceBergen's broader federal contract vehicle. The contractor, headquartered in Conshohocken, Pennsylvania, holds a...
- SPE2DB22D1002Indefinite Delivery Contract
- SPE2DB22D1002-SPE2DB25FLFB6Delivery Order
The Defense Logistics Agency awarded a $4,960.20 delivery order to AmerisourceBergen Drug Corp for supply of Entresto 24 mg-26 mg tablets (60-count) on July 21, 2025, with an ultimate completion date of July 22, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's comprehensive $999,999,999.00 IDC with DLA Troop Support Medical (contract number SPE2DX), which extends through December 2026 and functions as a global pharmaceutical support vehicle. The prime IDC enables the contractor to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including medications, vaccines, syringes, vials, and test kits. Entresto, a combination medication used primarily for heart failure treatment, supports the Defense Health Agency's medical supply requirements for military personnel and beneficiaries. AmerisourceBergen's substantial federal pharmaceutical distribution portfolio demonstrates the company's established capability to meet complex federal medical procurement requirements through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.0k | 7/21/25 |